deltatrials
Completed PHASE1 NCT00000954

A Study of Chemotherapy Plus ddI or ddC in the Treatment of AIDS-Related Kaposi's Sarcoma

Phase I/II Study of Combination Chemotherapy (Adriamycin, Bleomycin, +/- Vincristine) and Dideoxyinosine (ddI) or Dideoxycytidine (ddC) in the Treatment of AIDS-Related Kaposi's Sarcoma

Sponsor: Bristol-Myers Squibb

Conditions HIV Infections Sarcoma, Kaposi
Interventions Bleomycin sulfate Didanosine Doxorubicin hydrochloride Vincristine sulfate Zalcitabine
Updated 7 times since 2017 Last updated: Oct 27, 2021 Completion: Sep 30, 1996

This PHASE1 trial investigates HIV Infections and Sarcoma, Kaposi and is currently completed. Bristol-Myers Squibb leads this study, which shows 7 recorded versions since 2026 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE1

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE1

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  4. Nov 2021 — Jul 2024 [monthly]

    Completed PHASE1

  5. Jan 2021 — Nov 2021 [monthly]

    Completed PHASE1

▶ Show 2 earlier versions

  1. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1

  2. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bristol-Myers Squibb
  • National Institute of Allergy and Infectious Diseases (NIAID)
  • Novum
Data source: National Institute of Allergy and Infectious Diseases (NIAID)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aurora, United States, Baltimore, United States, Boston, United States, Buffalo, United States, Chapel Hill, United States, Chicago, United States, Columbus, United States, Indianapolis, United States, Los Angeles, United States, New York, United States and 2 more location s